Phase 1 Clinical Trials
First-in-human trials focused on safety, dosing and tolerability — the earliest clinical catalyst, in a small group of volunteers or patients.
December 20262
About Phase 1 Clinical Trials
Phase 1 clinical trials are the first time an experimental drug is tested in humans, typically in a small group of healthy volunteers or, in oncology, patients. The primary goals are to characterize safety, tolerability, dosing and pharmacokinetics — how the body absorbs and clears the drug.
While Phase 1 is not designed to prove efficacy, early signals of activity — especially in oncology dose-escalation studies — can still move a stock, and a clean safety profile is the ticket to advancing into Phase 2.
Why Phase 1 Trials matter to investors
Phase 1 catalysts matter most for early-stage and platform companies, where the first human data validates (or undermines) the underlying science. Safety signals, biomarker responses, or early efficacy hints can meaningfully re-rate a pre-revenue biotech, even though the absolute risk is high.
Frequently asked questions
What is a Phase 1 clinical trial?
A Phase 1 trial is the first-in-human study of a drug, focused on safety, tolerability and dosing in a small group of volunteers or patients rather than on proving it works.
Can Phase 1 results move a biotech stock?
Yes — a clean safety profile or early signs of activity (particularly in oncology) can re-rate an early-stage company, while a safety issue can halt a program.
What happens after Phase 1?
If safety and dosing are acceptable, the drug advances to Phase 2, where efficacy is tested in patients with the target disease.